CVR: 35481214
DKK -1,617,542
Gross profit
Net result: DKK -2,313,169
Ascelia Pharma AB
CVR · view ownership and management
Director registered: Magnus Olafsson Corfitzen
CVR · 30/06/2017
View the full event history
ONCORAL PHARMA ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Magnus Olafsson Corfitzen. The company is owned by Ascelia Pharma AB. The company has 0 employees (2014). In 2025, the company reported a gross profit of DKK -1,617,542 and a net result of DKK -2,313,169 compared with DKK -4,057,834 the year before. Equity in the 2025 report amounted to DKK -35,503,290.
Selskabet har til formål at gennemføre forsknings- og udviklingsaktiviteter relateret til udvikling af lægemidler, herunder særligt lægemidler i tabletform til behandling af cancer, og at udføre aktiviteter, som efter direktionens skøn er naturligt relaterede hertil.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -1.6 mio. | -2.3 mio. | 908 t. | -35.5 mio. | 1 | |
| 202401/01/2024 – 31/12/2024 | -367 t. | -4.1 mio. | 679 t. | -33.2 mio. | 1 | |
| 202301/01/2023 – 31/12/2023 | -996 t. | -2.7 mio. | 9.5 mio. | -29.1 mio. | 1 | |
| 202201/01/2022 – 31/12/2022 | -7.5 mio. | -9.2 mio. | 9.6 mio. | -26.5 mio. | - | |
| 202101/01/2021 – 31/12/2021 | -13.8 mio. | -11.8 mio. | 14.9 mio. | -17.3 mio. | - | |
| 202001/01/2020 – 31/12/2020 | -3.9 mio. | -3.5 mio. | 2.7 mio. | -5.4 mio. | - | |
| 201901/07/2018 – 30/06/2019 | -1.6 mio. | -1.5 mio. | 1.6 mio. | -1.4 mio. | - | |
| 201601/01/2016 – 31/12/2016 | -419 t. | -935 t. | 1.5 mio. | -4.5 mio. | 0 | |
| 201501/01/2015 – 31/12/2015 | -997 t. | -1 mio. | 1.9 mio. | -3.6 mio. | 0 |
Compared to 1.041 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningONCORAL PHARMA ApS was founded on 25 September 2013.
ONCORAL PHARMA ApS is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (industry code 721000).
ONCORAL PHARMA ApS had 0 employees in 2014 according to the Danish CVR register.
ONCORAL PHARMA ApS is owned by Ascelia Pharma AB.
In 2025, ONCORAL PHARMA ApS reported a gross profit of DKK -1,617,542.
The management of ONCORAL PHARMA ApS consists of Magnus Olafsson Corfitzen.
Claim this page to add your logo and social links. Free to get started.
ONCORAL PHARMA ApS has published its annual report for 2025. Gross profit came to DKK -1,617,542, and the net result was DKK -2,313,169.
Address changed to Amaliegade 6 2. tv 6, 2 tv, 1256 København K (February 1, 2026).
Contact info changed: new phone: 45484448, new email: [email protected] (February 1, 2026).
ONCORAL PHARMA ApS has published its annual report for 2024. Gross profit came to DKK -366,788, and the net result was DKK -4,057,834.
ONCORAL PHARMA ApS has published its annual report for 2023. Gross profit came to DKK -996,227, and the net result was DKK -2,667,242.
ONCORAL PHARMA ApS has published its annual report for 2022. Gross profit came to DKK -7,461,588, and the net result was DKK -9,206,889.
ONCORAL PHARMA ApS has published its annual report for 2021. Gross profit came to DKK -13,819,766, and the net result was DKK -11,818,103.
ONCORAL PHARMA ApS has published its annual report for 2020. Gross profit came to DKK -3,856,439, and the net result was DKK -3,458,277.
ONCORAL PHARMA ApS has published its interim report for the period July 1, 2019 – December 31, 2019.
ONCORAL PHARMA ApS has published its annual report for 2019. Gross profit came to DKK -1,623,620, and the net result was DKK -1,462,439.
ONCORAL PHARMA ApS has published its interim report for the period January 1, 2017 – June 30, 2018.
As of August 14, 2018, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ONCORAL PHARMA ApS.
As of August 14, 2018, KPMG P/S has stepped down as auditor of ONCORAL PHARMA ApS.
As of June 30, 2017, KPMG P/S has been appointed auditor of ONCORAL PHARMA ApS.
As of June 30, 2017, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of ONCORAL PHARMA ApS.
As of June 30, 2017, Mette Munch has left the board of directors of ONCORAL PHARMA ApS.
As of June 30, 2017, Ann Vivian Fullerton has left the board of directors of ONCORAL PHARMA ApS.
As of June 30, 2017, Peter Gudmund Nielsen has left the board of directors of ONCORAL PHARMA ApS.
As of June 30, 2017, Magnus Olafsson Corfitzen is registered as adm. dir. of ONCORAL PHARMA ApS.
As of June 30, 2017, Peter Gudmund Nielsen has stepped down as director of ONCORAL PHARMA ApS.
As of June 30, 2017, is registered as an owner of ONCORAL PHARMA ApS with an ownership share of 100%.
ONCORAL PHARMA ApS has published its annual report for 2016. Gross profit came to DKK -419,209, and the net result was DKK -934,525.
ONCORAL PHARMA ApS has published its annual report for 2015. Gross profit came to DKK -997,161, and the net result was DKK -1,046,198.
ONCORAL PHARMA ApS has published its interim report for the period September 25, 2013 – December 31, 2014.
As of February 9, 2015, Mette Munch has joined the board of directors of ONCORAL PHARMA ApS.
As of February 9, 2015, Jørn Frederik Falch has left the board of directors of ONCORAL PHARMA ApS.
As of September 25, 2013, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ONCORAL PHARMA ApS.
As of September 25, 2013, Jørn Frederik Falch has joined the board of directors of ONCORAL PHARMA ApS.
As of September 25, 2013, Ann Vivian Fullerton has joined the board of directors of ONCORAL PHARMA ApS.
As of September 25, 2013, Peter Gudmund Nielsen has joined the board of directors of ONCORAL PHARMA ApS.
As of September 25, 2013, Peter Gudmund Nielsen is registered as director of ONCORAL PHARMA ApS.
ONCORAL PHARMA ApS was founded on September 25, 2013.
Companies in the same industry and area
CVR 44695065
CVR 29418888
CVR 29769796
CVR 34688605
CVR 34892970
